SCHEMBL4257250

SCHEMBL4257250

Cn1nc(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)c(NC(=O)Nc3cccc(C(F)(F)F)c3)c2)c(C(N)=O)c1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.50
LCK P06239 3/20 0.50
FYN P06241 3/20 0.50
CSF1R P07333 3/20 0.50
LYN P07948 3/20 0.50
KIT P10721 3/20 0.50
SRC P12931 3/20 0.50
FLT1 P17948 3/20 0.50
FLT4 P35916 3/20 0.50
BLK P51451 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ABL1 P00519 2/20 0.50
FLT3 P36888 2/20 0.50
DYRK3 O43781 1/20 0.50
JAK2 O60674 1/20 0.50
ROCK2 O75116 1/20 0.50
MAP4K4 O95819 1/20 0.50
EGFR P00533 1/20 0.50
NTRK1 P04629 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6618727 0.92 EPHA3 (0.49) KDRLCKFYNCSF1RLYN
SCHEMBL4257173 0.91 KDR (0.58) KDRLCKFYNCSF1RLYN
SCHEMBL4260556 0.89 RIPK2 (0.53) KDRLCKSRCMEN1KMT2A
SCHEMBL6613292 0.87 KDR (0.55) KDRLCKFYNCSF1RLYN
SCHEMBL6614917 0.81 RIPK2 (0.51) KDRLCKFYNCSF1RLYN
SCHEMBL6614602 0.81 RIPK2 (0.50) KDRLCKFYNCSF1RLYN
SCHEMBL4260549 0.80 RET (0.57) KDRLCKFYNCSF1RLYN
SCHEMBL4257211 0.80 RIPK1 (0.53) KDRKITFLT1FLT4MEN1
SCHEMBL4260583 0.79 KDR (0.55) KDRLCKFYNCSF1RLYN
SCHEMBL4260093 0.76 AURKB (0.63) KDRLCKCSF1RLYNKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307097-B2 Chemical compounds SMITHKLINE BEECHMAN CORPORATION (US) 2007-12-11 US claimed
EP-1436265-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-12-15 EP claimed
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-10-07 US claimed
EP-1436265-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2004-07-14 EP claimed
WO-2003072541-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-04 WO claimed
US-20090012309-A1 CHEMICAL COMPOUNDS ADAMS JERRY LEROY 2009-01-08 US disclosed
US-7307097-B2 Chemical compounds SMITHKLINE BEECHMAN CORPORATION (US) 2007-12-11 US disclosed
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012309-A1 CHEMICAL COMPOUNDS CYP11B2, CYP3A43, CYP3A5 KDR 3847/4885LCK 1956/4885FYN 1972/4885
US-20040198986-A1 5-amino-1,3-substituted pyrazole-4-carboxylic acid amides of given formula, such as 5-Amino-1-tert-butyl-3-{4-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-1H-pyrazole-4-carboxylic acid amide; treating cancer; receptor tyrosine kinase inhibitors ERBB2, RET, ERBB4 KDR 191/4885LCK 45/4885FYN 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.